Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological therapy for obstructive sleep apnea
RBR-7w75qbyPhase 2Not yet recruiting
- Sponsor
- Universidade Federal do Rio Grande do Norte
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of reboxetine and oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (4 arms), sponsored by Universidade Federal do Rio Grande do Norte. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
reboxetineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on RBR-7w75qby.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7w75qby.